For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Flutemetamol Injection | \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels(MBq). | None | None | 0 | 7 | 7 | 7 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Blood Pressure Increase | SYSTEMATIC_ASSESSMENT | Investigations | MedDRA 10.0 | View |
| Blood Glucose Decrease | SYSTEMATIC_ASSESSMENT | Investigations | MedDRA 10.0 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Investigations | MedDRA 10.0 | View |
| Flushing | SYSTEMATIC_ASSESSMENT | Vascular disorders | MedDRA 10.0 | View |